Genticel Inks Over $20m Led by Wellington

Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), has raised 18.2 million euros ($23.7 million) in additional capital. Wellington Partners led the round which included all current institutional investors IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund*, IRDI and Amundi Private Equity Funds.

TxCell Raises $16M From InnoBio, Auriga, Seventure

TxCell SA said it raised $16 million in a third round of financing supported by the InnoBio fund, managed by CDC Entreprises, and existing shareholders Auriga Partners and Seventure Partners. InnoBio contributed about $7.8 million to the round.

DBV Technologies Adds $25.5 Million in Series C

Paris-based biotech company DBV Technologies has raised 19.4 million euros ($25.5 million) in a Series C round led by new investors InnoBio Fund and Lundbeckfond Ventures. Shire plc, ALTO Invest, Sofinnova Partners and ALK Abello also contributed to the round. DBV Technologies is developing products to combat food allergies such as peanut and milk. The company’s previous investors include Apax Partners, among others.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget